Drugs / Cultured Autologous Skeletal Myoblast Transplantation
Cultured Autologous Skeletal Myoblast Transplantation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00102128 | Nov 2002 → Apr 2007 | cardiomyopathy, heart failure, myocardial ischemia | Genzyme, a Sanofi Company | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cultured Autologous Skeletal Myoblast Transplantation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00102128 ↗ |
| Modality | Cell therapy | “implanted skeletal muscle cells (cells removed from the thigh muscle)” NCT00102128 ↗ |
| Route | Other | “implanted skeletal muscle cells (cells removed from the thigh muscle) into scarred areas of heart muscle after heart attack” NCT00102128 ↗ |